351 related articles for article (PubMed ID: 14500467)
1. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.
Liang W; Wang S; Yu F; Zhang L; Qi G; Liu Y; Gao S; Kan B
Infect Immun; 2003 Oct; 71(10):5498-504. PubMed ID: 14500467
[TBL] [Abstract][Full Text] [Related]
2. Resistance of the cholera vaccine candidate IEM108 against CTXPhi infection.
Liu G; Yan M; Liang W; Qi G; Liu Y; Gao S; Kan B
Vaccine; 2006 Mar; 24(11):1749-55. PubMed ID: 16343705
[TBL] [Abstract][Full Text] [Related]
3. A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infection.
Yan M; Liu G; Diao B; Qiu H; Zhang L; Liang W; Gao S; Kan B
Vaccine; 2007 May; 25(20):4046-55. PubMed ID: 17428586
[TBL] [Abstract][Full Text] [Related]
4. Construction and characterization of a thyA mutant derived from cholera vaccine candidate IEM101.
Yu F; Qi G; Liu Y; Gao S; Kan B
Mol Biotechnol; 2005 Mar; 29(3):191-6. PubMed ID: 15767696
[TBL] [Abstract][Full Text] [Related]
5. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
[TBL] [Abstract][Full Text] [Related]
6. CTXphi immunity: application in the development of cholera vaccines.
Kimsey HH; Waldor MK
Proc Natl Acad Sci U S A; 1998 Jun; 95(12):7035-9. PubMed ID: 9618534
[TBL] [Abstract][Full Text] [Related]
7. IEM101, a naturally attenuated Vibrio cholerae strain as carrier for genetically detoxified derivatives of cholera toxin.
Fontana MR; Monaci E; Yanqing L; Guoming Q; Duan G; Rappuoli R; Pizza M
Vaccine; 2000 Aug; 19(1):75-85. PubMed ID: 10924789
[TBL] [Abstract][Full Text] [Related]
8. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
Kundu J; Mazumder R; Srivastava R; Srivastava BS
FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
[TBL] [Abstract][Full Text] [Related]
9. Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.
Murugaiah C; Nik Mohd Noor NZ; Mustafa S; Manickam R; Pattabhiraman L
PLoS One; 2014; 9(2):e81817. PubMed ID: 24505241
[TBL] [Abstract][Full Text] [Related]
10. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
[TBL] [Abstract][Full Text] [Related]
11. Cholera toxin-B (ctxB) antigen expressing Salmonella Typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection.
Vishwakarma V; Sahoo SS; Das S; Ray S; Hardt WD; Suar M
Vaccine; 2015 Apr; 33(15):1880-9. PubMed ID: 25701672
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
[TBL] [Abstract][Full Text] [Related]
13. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
Kenner JR; Coster TS; Taylor DN; Trofa AF; Barrera-Oro M; Hyman T; Adams JM; Beattie DT; Killeen KP; Spriggs DR
J Infect Dis; 1995 Oct; 172(4):1126-9. PubMed ID: 7561195
[TBL] [Abstract][Full Text] [Related]
14. Construction of a recombinant live oral vaccine from a non-toxigenic strain of Vibrio cholerae O1 serotype inaba biotype E1 Tor and assessment of its reactogenicity and immunogenicity in the rabbit model.
Thungapathra M; Sharma C; Gupta N; Ghosh RK; Mukhopadhyay A; Koley H; Nair GB; Ghosh A
Immunol Lett; 1999 Jun; 68(2-3):219-27. PubMed ID: 10424424
[TBL] [Abstract][Full Text] [Related]
15. Heterologous antigen expression in Vibrio cholerae vector strains.
Butterton JR; Beattie DT; Gardel CL; Carroll PA; Hyman T; Killeen KP; Mekalanos JJ; Calderwood SB
Infect Immun; 1995 Jul; 63(7):2689-96. PubMed ID: 7790086
[TBL] [Abstract][Full Text] [Related]
16. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
Liao J; Gibson JA; Pickering BS; Watnick PI
mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
[TBL] [Abstract][Full Text] [Related]
17. CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain.
Michalski J; Galen JE; Fasano A; Kaper JB
Infect Immun; 1993 Oct; 61(10):4462-8. PubMed ID: 8406837
[TBL] [Abstract][Full Text] [Related]
18. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
19. Investigation into immunological responses against a native recombinant CTB whole-cell Vibrio cholerae vaccine in a rabbit model.
Boustanshenas M; Bakhshi B; Ghorbani M
J Appl Microbiol; 2013 Feb; 114(2):509-15. PubMed ID: 23082752
[TBL] [Abstract][Full Text] [Related]
20. Construction of a Vibrio cholerae prototype vaccine strain O395-N1-E1 which accumulates cell-associated cholera toxin B subunit.
Rhie GE; Jung HM; Kim BS; Mekalanos JJ
Vaccine; 2008 Oct; 26(43):5443-8. PubMed ID: 18582519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
